ZAI LAB LIMITED - AMERICAN DEPOSITARY SHARES

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

27 апр 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

26 апр 2023 09:25:30 Источник Nasdaq GlobeNewswire

Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023

20 апр 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

11 апр 2023 07:03:00 Источник Nasdaq GlobeNewswire

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

20 мар 2023 05:35:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates

01 мар 2023 15:01:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Participation in March Investor Conferences

28 фев 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress

22 фев 2023 15:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA

22 фев 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023

09 фев 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Participation in February Investor Conferences

31 янв 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

30 янв 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

18 янв 2023 06:49:38 Источник Nasdaq GlobeNewswire

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

09 янв 2023 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

05 янв 2023 06:34:15 Источник Nasdaq GlobeNewswire

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

03 янв 2023 07:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Participation in January Investor Conferences

20 дек 2022 06:30:00 Источник Nasdaq GlobeNewswire

Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

15 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

05 дек 2022 17:10:00 Источник Nasdaq GlobeNewswire

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

09 ноя 2022 15:01:00 Источник Nasdaq GlobeNewswire